Clayton M. Christensen's Blog, page 7
December 7, 2018
Webinar: Unite Your Senior Team
Download a copy of the presentation
Leadership alignment is a persistent challenge. CEOs and senior teams often seem aligned on strategy – but in fact can be plagued by divisions and doubts just below the surface. The lack of unity can create paralysis and derail critical initiatives
The problem is a human one – and it’s solvable.
Watch Innosight’s Bernard Kümmerli and Scott Anthony, authors of the new Harvard Business Review article “Unite Your Senior Team,” as they share a programmatic approach to getting your leadership team aligned around a strategy for the future. 
Read our HBR article ‘Unite Your Senior Team’
Drawing on thinking from neuroscience and behavioral psychology, and work with corporate leaders, Bernard and Scott explore:
What causes leadership misalignment – and why it is so persistent
How executive teams can establish a foundation of common language and understanding for the future
How “Walk the Line” and other innovative exercises can help leaders expose hidden misalignment
A case study on how the leadership team of Swisscom converged on a “North Star” long-term growth strategy
Watch the webinar on-demand
The post Webinar: Unite Your Senior Team appeared first on Innosight.
Webinar: “Unite Your Senior Team”
Download a copy of the presentation
Leadership alignment is a persistent challenge. CEOs and senior teams often seem aligned on strategy – but in fact can be plagued by divisions and doubts just below the surface. The lack of unity can create paralysis and derail critical initiatives
The problem is a human one – and it’s solvable.
Watch Innosight’s Bernard Kümmerli and Scott Anthony, authors of the new Harvard Business Review article “Unite Your Senior Team,” as they share a programmatic approach to getting your leadership team aligned around a strategy for the future.
Read our HBR article ‘Unite Your Senior Team’
Drawing on thinking from neuroscience and behavioral psychology, and work with corporate leaders, Bernard and Scott explore:
What causes leadership misalignment – and why it is so persistent
How executive teams can establish a foundation of common language and understanding for the future
How “Walk the Line” and other innovative exercises can help leaders expose hidden misalignment
A case study on how the leadership team of Swisscom converged on a “North Star” long-term growth strategy
The post Webinar: “Unite Your Senior Team” appeared first on Innosight.
December 5, 2018
The Best of 2018
The post The Best of 2018 appeared first on Innosight.
November 30, 2018
November 15, 2018
LEADING TRANSFORMATION
The post LEADING TRANSFORMATION appeared first on Innosight.
November 14, 2018
Daimler’s Wilfried Porth on Building Strategy in Times of Change
BUILDING STRATEGY IN TIMES OF CHANGE
Wilfried Porth, Member of the Board of Management, Daimler AG
2018 CEO Summit Munich
How do new opportunities help shape Daimler’s strategy?
“Looking into the future, there are a lot of challenges ahead; digitization, autonomous driving, the sharing economy. There are new competitors coming up. And those are the things we have to deal with. Now there are lot of opinions about what will be the breakthrough at the end of the day. And we do believe that there will be a little bit of everything at the end of the day. So, we need to invest in all those channels. We won’t be the better Googles or the better Apples.
What are some of your most promising new growth ventures?
car2go we have in several cities in the world, for example, Amsterdam, Stuttgart. We have fleets running of Smart cars of our small cars. And you can sign up and then you can take a ride whenever you need and whenever a car is available nearby. And then you drop the car wherever you stop. And that’s quite a challenge because your business case depends very much on the usage of the cars and you don’t know exactly where cars are being needed in the near future. So that’s quite a complex business model, but it’s something we are testing and then we are actually at the moment the biggest in Europe.
Where will future innovation come from?
Thing like the anti-locking system for brakes and a lot of other innovations came through the premium cars and they did not come through the mass production cars. Nevertheless, I think especially in China starting with electric vehicles in the mass market with very cheap, very simple vehicles will definitely prepare the base for better batteries in the future. And that will also support the premium market. That’s not a field we want to go in, but we would definitely benefit from it at the end of the day.
What do you see remaining the same in the future?
So, there are opportunities for us to grow. When it comes to the overall perspective on automotive industry, I am very confident that we are able to adapt and cooperate with those companies to master the future challenges like autonomous driving, like sharing, because we are providing the physical assets. And those are still the base of whatever happens in the future.”
The post Daimler’s Wilfried Porth on Building Strategy in Times of Change appeared first on Innosight.
Wilfried Porth on Building Strategy in Times of Change
BUILDING STRATEGY IN TIMES OF CHANGE
Wilfried Porth, Member of the Board of Management, Daimler AG
2018 CEO Summit Munich
“Looking into the future, there are a lot of challenges ahead; digitization, autonomous driving, the sharing economy. There are new competitors coming up. And those are the things we have to deal with. Now there are lot of opinions about what will be the breakthrough at the end of the day. And we do believe that there will be a little bit of everything at the end of the day. So, we need to invest in all those channels. We won’t be the better Googles or the better Apples.
car2go we have in several cities in the world, for example, Amsterdam, Stuttgart. We have fleets running of Smart cars of our small cars. And you can sign up and then you can take a ride whenever you need and whenever a car is available nearby. And then you drop the car wherever you stop. And that’s quite a challenge because your business case depends very much on the usage of the cars and you don’t know exactly where cars are being needed in the near future. So that’s quite a complex business model, but it’s something we are testing and then we are actually at the moment the biggest in Europe.
Thing like the anti-locking system for brakes and a lot of other innovations came through the premium cars and they did not come through the mass production cars. Nevertheless, I think especially in China starting with electric vehicles in the mass market with very cheap, very simple vehicles will definitely prepare the base for better batteries in the future. And that will also support the premium market. That’s not a field we want to go in, but we would definitely benefit from it at the end of the day.
So, there are opportunities for us to grow. When it comes to the overall perspective on automotive industry, I am very confident that we are able to adapt and cooperate with those companies to master the future challenges like autonomous driving, like sharing, because we are providing the physical assets. And those are still the base of whatever happens in the future.”
The post Wilfried Porth on Building Strategy in Times of Change appeared first on Innosight.
November 12, 2018
3 Business Models That Could Bring Million-Dollar Cures to Everyone
When the FDA issued its first approval for a gene therapy for an inherited disease nearly a year ago—a cure for a type of blindness—it was heralded as breakthrough, a moment decades in the making. With dozens of other genetically engineered therapies moving through clinical trials, the long-promised era of personalized, gene-based medicine seemed to be at hand.
But there was a catch: the one-time treatment, Luxturna from Spark Therapeutics, costs $850,000.
In a recent Goldman Sachs research report about the promise of gene therapies, analysts asked a question that gets to the heart of a growing dilemma for the healthcare sector: “Is curing patients a sustainable business model?” As this first wave of genetic treatments hits the market, industry leaders face a stark choice. These therapies could save or change lives, but they come at unprecedented cost. Indeed, Novartis recently said that its life-saving gene therapy for spinal muscular atrophy would be “cost-effective” at $4 million to $5 million – hinting at the pricing the company has in mind. As the use of these expensive drugs grows, there seems to be no way traditional insurance models will be able to pay for them without breaking the bank or requiring patients to assume a big chunk of the cost.
Consider what happened to Amsterdam-based UniQure. In 2016, the company had to pull its gene therapy for potentially fatal fat-processing deficiencies from the E.U. market. With a $1 million price tag, limited data on efficacy and just 700 potential patients in Europe, health systems were unwilling to pay for treatment. Biopharma companies now have 58 gene therapies and gene-modified cell treatments in Phase III clinical trials, with about 35 expected to be FDA-approved by 2022, out of about 1,000 candidates in the total pipeline. These new therapies could face a similar fate if prices can’t be brought down. Something has got to give.
New business models
Our research on major innovations finds that when disruption occurs, technologies don’t replace technologies; systems replace systems. Put another way, product classes with fundamentally new performance profiles can’t be dropped into an existing business model and expected to work. The business model — how value is created, captured, and delivered — needs to be reinvented to support the new proposition.
When it comes to gene therapies, there’s a growing recognition that harnessing breakthrough science to cure diseases simply isn’t enough. Some industry innovators are creating novel payment models that share the risks and costs in ways that may help jump-start new markets and cure more patients. Some of these new models are already being rolled out — and others are more theoretical. But they illustrate the levers companies can pull in order to make therapies more affordable and accessible.
Read the full article ON Harvard Business Review
The post 3 Business Models That Could Bring Million-Dollar Cures to Everyone appeared first on Innosight.
October 22, 2018
Unite Your Senior Team
The post Unite Your Senior Team appeared first on Innosight.
Clayton M. Christensen's Blog
- Clayton M. Christensen's profile
- 2167 followers
